vs
Liberty Broadband Corp（LBRDA）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
Liberty Broadband Corp的季度营收约是Pacira BioSciences, Inc.的1.5倍（$261.0M vs $177.4M），Liberty Broadband Corp净利率更高（146.7% vs 1.6%，领先145.1%），Liberty Broadband Corp同比增速更快（6.1% vs 5.0%），过去两年Liberty Broadband Corp的营收复合增速更高（4.3% vs -0.2%）
本公司是一家覆盖英、荷、美三地的跨国电信企业，注册地为百慕大，在伦敦、阿姆斯特丹、丹佛设有总部，旗下拥有多家对应司法辖区的运营主体，其中英国主体为公开上市实体，2005年由自由媒体国际业务板块与UnitedGlobalCom合并成立。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
LBRDA vs PCRX — 直观对比
营收规模更大
LBRDA
是对方的1.5倍
$177.4M
营收增速更快
LBRDA
高出1.1%
5.0%
净利率更高
LBRDA
高出145.1%
1.6%
两年增速更快
LBRDA
近两年复合增速
-0.2%
损益表 — Q2 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $261.0M | $177.4M |
| 净利润 | $383.0M | $2.9M |
| 毛利率 | — | — |
| 营业利润率 | 15.7% | 3.9% |
| 净利率 | 146.7% | 1.6% |
| 营收同比 | 6.1% | 5.0% |
| 净利润同比 | 96.4% | — |
| 每股收益（稀释后） | $2.68 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LBRDAPCRX
| Q1 26 | — | $177.4M | ||
| Q4 25 | — | $196.9M | ||
| Q3 25 | — | $179.5M | ||
| Q2 25 | $261.0M | $181.1M | ||
| Q1 25 | $266.0M | $168.9M | ||
| Q4 24 | $263.0M | $187.3M | ||
| Q3 24 | $262.0M | $168.6M | ||
| Q2 24 | $246.0M | $178.0M |
净利润LBRDAPCRX
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $5.4M | ||
| Q2 25 | $383.0M | $-4.8M | ||
| Q1 25 | $268.0M | $4.8M | ||
| Q4 24 | $291.0M | — | ||
| Q3 24 | $142.0M | $-143.5M | ||
| Q2 24 | $195.0M | $18.9M |
毛利率LBRDAPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
营业利润率LBRDAPCRX
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | 15.7% | 4.7% | ||
| Q1 25 | 16.2% | 1.2% | ||
| Q4 24 | 4.9% | 13.2% | ||
| Q3 24 | 11.5% | -82.8% | ||
| Q2 24 | 8.5% | 15.9% |
净利率LBRDAPCRX
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 3.0% | ||
| Q2 25 | 146.7% | -2.7% | ||
| Q1 25 | 100.8% | 2.8% | ||
| Q4 24 | 110.6% | — | ||
| Q3 24 | 54.2% | -85.1% | ||
| Q2 24 | 79.3% | 10.6% |
每股收益（稀释后）LBRDAPCRX
| Q1 26 | — | $0.07 | ||
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | $2.68 | $-0.11 | ||
| Q1 25 | $1.87 | $0.10 | ||
| Q4 24 | $2.04 | $0.38 | ||
| Q3 24 | $0.99 | $-3.11 | ||
| Q2 24 | $1.36 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.0M | $144.3M |
| 总债务越低越好 | $3.1B | — |
| 股东权益账面价值 | $10.4B | $653.9M |
| 总资产 | $16.6B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.30× | — |
8季度趋势，按日历期对齐
现金及短期投资LBRDAPCRX
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | $180.0M | $445.9M | ||
| Q1 25 | $226.0M | $493.6M | ||
| Q4 24 | $163.0M | $484.6M | ||
| Q3 24 | $168.0M | $453.8M | ||
| Q2 24 | $73.0M | $404.2M |
总债务LBRDAPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | $3.1B | $580.5M | ||
| Q1 25 | $3.8B | $583.4M | ||
| Q4 24 | $3.8B | $585.3M | ||
| Q3 24 | $3.7B | — | ||
| Q2 24 | $3.6B | — |
股东权益LBRDAPCRX
| Q1 26 | — | $653.9M | ||
| Q4 25 | — | $693.1M | ||
| Q3 25 | — | $727.2M | ||
| Q2 25 | $10.4B | $757.8M | ||
| Q1 25 | $10.1B | $798.5M | ||
| Q4 24 | $9.8B | $778.3M | ||
| Q3 24 | $9.5B | $749.6M | ||
| Q2 24 | $9.3B | $879.3M |
总资产LBRDAPCRX
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $16.6B | $1.5B | ||
| Q1 25 | $17.0B | $1.6B | ||
| Q4 24 | $16.7B | $1.6B | ||
| Q3 24 | $16.3B | $1.5B | ||
| Q2 24 | $16.0B | $1.6B |
负债/权益比LBRDAPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | 0.30× | 0.77× | ||
| Q1 25 | 0.38× | 0.73× | ||
| Q4 24 | 0.38× | 0.75× | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 0.39× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $91.0M | — |
| 自由现金流经营现金流 - 资本支出 | $37.0M | — |
| 自由现金流率自由现金流/营收 | 14.2% | — |
| 资本支出强度资本支出/营收 | 20.7% | — |
| 现金转化率经营现金流/净利润 | 0.24× | — |
| 过去12个月自由现金流最近4个季度 | $-49.0M | — |
8季度趋势，按日历期对齐
经营现金流LBRDAPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | $43.7M | ||
| Q3 25 | — | $60.8M | ||
| Q2 25 | $91.0M | $12.0M | ||
| Q1 25 | $78.0M | $35.5M | ||
| Q4 24 | $1.0M | $33.1M | ||
| Q3 24 | $24.0M | $53.9M | ||
| Q2 24 | $27.0M | $53.2M |
自由现金流LBRDAPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | $37.0M | $9.3M | ||
| Q1 25 | $13.0M | $26.9M | ||
| Q4 24 | $-63.0M | $31.0M | ||
| Q3 24 | $-36.0M | $49.8M | ||
| Q2 24 | $-35.0M | $51.6M |
自由现金流率LBRDAPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | 14.2% | 5.1% | ||
| Q1 25 | 4.9% | 15.9% | ||
| Q4 24 | -24.0% | 16.6% | ||
| Q3 24 | -13.7% | 29.6% | ||
| Q2 24 | -14.2% | 29.0% |
资本支出强度LBRDAPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | 20.7% | 1.5% | ||
| Q1 25 | 24.4% | 5.1% | ||
| Q4 24 | 24.3% | 1.1% | ||
| Q3 24 | 22.9% | 2.4% | ||
| Q2 24 | 25.2% | 0.9% |
现金转化率LBRDAPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | 0.24× | — | ||
| Q1 25 | 0.29× | 7.37× | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.17× | — | ||
| Q2 24 | 0.14× | 2.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LBRDA
暂无分部数据
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
